Evidence map›Paper›PMID 41303366›Full record

ArticleInternational journal of molecular sciences2025

In Vitro and In Silico Evaluation of a Novel Multifunctional Cyclic Peptide with Antioxidant, Tyrosinase-Inhibitory, and Extracellular Matrix-Modulating Activities.

Ga-Hyun Kim, Bo-Mi Kim

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ga-Hyun KimDepartment of Chemical Engineering, Wonkwang University, Iksan-si 54538, Jeollabuk-do, Republic of Korea.ORCID 0009-0009-0219-4586
Bo-Mi KimDepartment of Chemical Engineering, Wonkwang University, Iksan-si 54538, Jeollabuk-do, Republic of Korea.ORCID 0009-0009-8546-7980

Funding

This research was supported by the Regional Innovation System and Education (RISE) program through the Jeonbuk RISE Center, funded by the Ministry of Education (MOE) and Jeonbuk State, Republic of Korea.(2025-RISE-13-WKU) and the "Glocal 30" Project. Supp 2025-RISE-13-WKU
6 · The paper itself

Abstract

Peptides are notable cosmetic ingredients owing to their diverse biological activities and beneficial effects on skin health. Therefore, multifunctional peptides capable of simultaneously exerting antioxidant, whitening, and anti-wrinkle effects are highly desirable. In this study, a scalable and cost-effective chemical synthesis strategy was used for the rapid design and synthesis of linear peptide sequences with skin bioactivity using solid-phase peptide synthesis. Subsequently, liquid-phase peptide synthesis was used to enhance the proteolytic stability and develop a cyclic peptide, cyclic CYGSR (CR5), which was subjected to in vitro biological evaluation. CR5 showed high biocompatibility in water-soluble tetrazolium salt-1 (WST-1) assays, maintaining over 90% cell viability at concentrations up to 400 μg/mL. In the 2,2-Diphenyl-1-picrylhydrazy (DPPH) assay, CR5 exhibited strong antioxidant activity with 83.18% radical scavenging at 200 μg/mL. It also showed 97.79% tyrosinase inhibition at 800 μg/mL, confirming significant whitening potential. Moreover, CR5 inhibited matrix metalloproteinase-1 (MMP-1) expression by 73.55% and increased type I procollagen expression by 44.68% at 400 μg/mL, demonstrating its anti-wrinkle potential. Additionally, molecular docking and dynamic simulation demonstrated stable binding of the peptide to tyrosinase and MMP-1. Collectively, CR5 possesses multifunctional properties with excellent biocompatibility, highlighting its potential as a novel cosmetic active ingredient.

Indexed as

AntioxidantsEnzyme InhibitorsExtracellular MatrixMonophenol MonooxygenasePeptides, CyclicCell SurvivalHumansMatrix Metalloproteinase 1Molecular Docking SimulationAntioxidantsEnzyme InhibitorsMatrix Metalloproteinase 1Monophenol MonooxygenasePeptides, Cycliccyclic peptideDPPH radical scavenging activityMMP-1molecular dockingprocollagentyrosinase inhibition

Identifiers

PMID41303366
PMCPMC12652428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.